Thermo Fisher Scientific (TMO) PT Raised to $610 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the price target on Thermo Fisher Scientific (NYSE: TMO) to $610.00 (from $590.00) while maintaining a Outperform rating.

The analyst comments "Thesis Update: TMO had a good print, reaffirming the stabilization / turnaround theme. Organic came in slightly better, driven by AI (Inst) strength on biopharma & Industrial demand & slightly better A&G mkts. OM execution was solid (110 bps above ST) - while 1/3 of this was lower tariff HWs, majority came from OpEx mgmt. With ST #s set appropriately for FY26, we see TMO as a play on LST end mkt recovery. Our FY26 est incr by ~2% causing us to raise our PT to $610 This report is prepared solely for the use of Michael Bloom (equates to ~25x CY26 P/E & 3.4% FCF yield)."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy